ViewRay Technologies, Inc.

ViewRay Technologies, Inc. is a leader in medical technology, specializing in MRI-guided radiation therapy systems that enhance precision in cancer treatment through real-time imaging and automated delivery of radiation. ViewRay Technologies, Inc. develops innovative MRI-guided radiation therapy systems, enabling precise cancer treatment.

Founded in 2004 in the United States, the company went public in July 2015 through a reverse merger. During this transaction, it raised USD 26. 70 mn from a private placement. The firm has completed 26 deals since its inception, signaling active engagement in the healthcare technology sector.

ViewRay Technologies, Inc. focuses on the MRIdian A3i, an MRI-guided radiation therapy system that utilizes high-quality MRI imaging to enhance the accuracy of cancer treatments. Its technology enables real-time tracking of soft tissues, improving dose delivery to tumors without the need for implanted markers. The MRIdian A3i serves hospitals, cancer treatment centers, and oncology professionals, and is marketed in North America, Europe, and parts of Asia, targeting a global clientele committed to enhancing cancer care.

In 2022, ViewRay generated revenue of USD 102. 21 mn, with an EBITDA of USD -101. 28 mn, reflecting the company's ongoing investment in developing advanced medical technology while establishing long-term partnerships with healthcare providers through service contracts and upgrades. ViewRay Technologies, Inc.

aims to expand its product line, focusing on the upcoming releases of enhanced versions of the MRIdian A3i to meet growing demand in the oncology sector. The company is targeting expansion into additional markets in Europe and Asia by 2025, leveraging recent funding from a Private Placement in July 2015 to support these initiatives. This funding will enable the company to further its research and development efforts, ensuring they remain at the forefront of oncology technology.